Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Fiche publication
Date publication
février 2018
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A,
Lien Pubmed
Résumé
The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity.
Mots clés
Adolescent, Adult, Antibodies, Monoclonal, Humanized, therapeutic use, Arthritis, drug therapy, Cohort Studies, Colitis, Ulcerative, complications, Crohn Disease, complications, Female, France, epidemiology, Humans, Inflammation, drug therapy, Inflammatory Bowel Diseases, complications, Middle Aged, Skin Diseases, drug therapy, Young Adult
Référence
Aliment. Pharmacol. Ther.. 2018 02;47(4):485-493